Drug launches during COVID-19 was a significant topic during
the Summit. A recent TGaS benchmarking survey showed that 89 percent of
companies have had an impact to their pre-launch activities due to COVID-19,
with almost half of these companies reporting high impact.
One white paper that was distributed to attendees at the
Summit was entitled: Approaching
Launch in the Age of COVID-19, The New Normal for Drug Launches: How to Shift
and Stay Ahead of the Curve. The paper finds that there are four
“must-have” needs to set the stage for a successful launch during the pandemic:
- Recognize
and adopt a mindset of change - Customer-driven
flexibility - Organizational
flexibility: planning, communication and alignment - Data-driven
flexibility
“The show must go on,” said Curt Staab, SVP, TGaS
Advisors, a division of Trinity. “Drugs will and must launch during this
pandemic, but a shift in mindset is needed to ensure success. The needs we
detail in this paper are not new, they have been taking root for many years,
but COVID-19 is bringing them to the surface and accelerating the need for
pharma teams to be flexible and agile.”
A
copy of Approaching Launch in
the Age of COVID-19, The New Normal for Drug Launches: How to Shift and Stay
Ahead of the Curve can be acquired on TrinityLifeSciences.com.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
For more information:
Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com